Soft tissue sarcoma test kit SARCOPACT™

oncologyfor precision medicineTMB

Sarcoma is a broad term for cancers that arise from the soft tissues or bones. Soft tissue sarcomas develop in fat, muscles, nerves, fibrous tissues, blood vessels or deep skin tissues while bone sarcomas originate in bone. Treatment options vary depending on the size, location and type of tumor. Generally, surgery, radiation therapy, chemotherapy and targeted drug treatment are considered. Despite the effectiveness of traditional therapies, 50% patients develop metastasis and 10-20% experience recurrence. Targets 506 key genes in soft tissue and bone tumors Sarcopact™ employs DNA targeted sequencing to detect single nucleotide variants (SNVs), small insertions and deletions (indels), copy number variations (CNVs), and selected gene fusions to characterize sarcoma subtypes; it also assesses key biomarkers including tumour mutation burden (TMB), micro satellite instability (MSI), and DNA mismatch repair (MMR) genes to guide immunotherapy decision Coverage of prognosis-related genes to inform treatment decision making Coverage of sarcoma-related, and clinically actionable gene alterations to guide targeted therapy Timely assessment of drug resistance and associated mechanism(s) through liquid biopsy to direct treatment strategy Hereditary cancer risk assessment for early intervention  WHO IS IT FOR Sarcoma patients seeking precision medicine Patients with unresectable or metastatic sarcomas Sarcoma patients with recurrent disease  Patients with an early onset or family history of sarcomas SAMPLE TYPES Tumor tissue (FFPE block/slides, or frozen tissue) Fine needle biopsy Liquid biopsy (plasma and others)